Impact of cancer treatments on healthy tissue genetics

Recent medical research has highlighted how cancer treatments can induce genetic changes and long-term damage in healthy tissues.

Studies involving esophageal cancer patients found that chemotherapy and chemoradiotherapy can alter the genetic makeup of healthy tissue by providing an evolutionary advantage to existing mutant cells. Specifically, chemoradiotherapy was linked to an increase in healthy cells carrying mutations in the TP53 and PPM1D genes. Furthermore, combined chemotherapy appeared to select for mutant cells resistant to the drug 5-fluorouracil, potentially reshaping the genetic landscape of healthy tissue within weeks.

In pediatric oncology, research indicates that platinum-based chemotherapy drugs used to treat childhood cancers can leave a genetic signature on the liver. In patients treated for hepatoblastoma, healthy liver cells exhibited mutation levels similar to adult livers, suggesting premature tissue aging. Additionally, researchers identified a link between the stem cell molecule UM171 and cellular breakdowns that mirror genetic mutations found in aggressive pediatric brain tumors, such as medulloblastomas.